ArticleNPJ precision oncology2024

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.

Takaaki Fujimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.